GlassScriptPhysician profile
Michael Yeboah
NPI 1285253559
$7,172.28
in general payments reported to CMS, 2019-2025
28 companies · $4,754 in 2025
The $4,754 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $147 · 2022: $333 · 2023: $233 · 2024: $1,705 · 2025: $4,754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,692.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,011.41 | 2024-2025 | Yeztugo, Descovy, Epclusa |
| Lilly USA, LLC | $723.50 | 2021-2025 | Zepbound, Mounjaro, Trulicity |
| Novo Nordisk INC | $693.20 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $670.04 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $602.50 | 2025 | Repatha, Otezla, Krystexxa |
| Abbvie INC. | $562.12 | 2023-2025 | |
| Glaxosmithkline, LLC. | $455.98 | 2021-2025 | Nucala, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $413.37 | 2024-2025 | |
| Genzyme Corporation | $284.96 | 2024-2025 | |
| Dexcom, INC. | $244.11 | 2024-2025 | Dexcom G6 Transmitter, Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Kowa Pharmaceuticals America, INC. | $232.64 | 2025 | Zoryve |
| Viiv Healthcare Company | $225.82 | 2025 | Apretude |
| Merck Sharp & Dohme LLC | $158.33 | 2021-2023 | Pneumovax 23, Vaxneuvance, Gardasil 9 |
| Pfizer INC. | $158.33 | 2023-2025 | |
| Verona Pharma, INC. | $103.28 | 2025 | Ohtuvayre |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $102.31 | 2025 | Dupixent |
| Sobi, INC | $84.32 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $83.57 | 2022-2023 | Abilify Maintena, Rexulti |
| Janssen Pharmaceuticals, INC | $72.12 | 2022 | |
| Scilex Pharmaceuticals INC. | $70.78 | 2025 | |
| Aimmune Therapeutics, INC. | $68.03 | 2024-2025 | Zenpep |
| Cranial Technologies, INC | $31.05 | 2022-2023 | Doc Band |
| Electromed, INC. | $28.42 | 2025 | Smartvest |
| Sanofi Pasteur INC. | $21.43 | 2022 | |
| Phathom Pharmaceuticals, INC. | $20.89 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $18.85 | 2025 | Eliquis |
| Biohaven Pharmaceutical Holding Company LTD. | $17.40 | 2022 | |
| Lundbeck LLC | $13.52 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Yeboah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.